Clinical Trials Directory

Trials / Recruiting

RecruitingNCT00842283

Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

Status
Recruiting
Phase
Study type
Observational
Enrollment
85 (estimated)
Sponsor
University of California, Irvine · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Accepted

Summary

The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways. De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.

Detailed description

Biospecimens from various dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis will be evaluated for markers of angiogenesis. Additionally, researchers can use discarded human skin tissue samples from skin biopsy/surgery sites, which are removed for closure but are not submitted for histopathologic analysis. We may use donated tissue with both dermatologic disease and non-diseased tissue from the same donor. Biopsies may also be taken for molecular and genetic analysis of specimen. Non-identifiable information regarding the patient, such as age, sex, race, cause of death, location, and description of diseased skin may be recorded.

Conditions

Interventions

TypeNameDescription
OTHERskin tissue sampleskin tissue sample

Timeline

Start date
2008-11-01
Primary completion
2028-12-01
Completion
2028-12-01
First posted
2009-02-12
Last updated
2026-04-13

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00842283. Inclusion in this directory is not an endorsement.